Medical Oncologist
ALK-positive lung cancer
Who Is Eligible for — Alectinib?
Alectinib is a targeted treatment for a specific type of lung cancer. Whether it applies to you depends on a single test result — not your symptoms, your stage, or how long you have been unwell.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- One test decides — Eligibility rests on your ALK biomarker result, not on your cancer stage or smoking history.
- Most lung cancer patients are not eligible — ALK rearrangement is found in only a small proportion of people with non-small cell lung cancer.
- Brain spread does not rule you out — Alectinib reaches the brain more effectively than earlier ALK inhibitors and is used when the cancer has spread there.
- A negative result is not a dead end — ALK-negative patients have other targeted or systemic options — eligibility means finding the right match, not a closed door.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Alectinib is for people with ALK-positive non-small cell lung cancer, confirmed by an approved biomarker test on tumour tissue. If your ALK result is negative, or if you have a different cancer type such as small cell lung cancer, alectinib will not help you and is not recommended. The test result, not your symptoms or stage, is what determines eligibility.
What test decides whether alectinib is right for you?
ALK stands for anaplastic lymphoma kinase. In a small proportion of people with non-small cell lung cancer, the ALK gene has rearranged in a way that drives tumour growth. Alectinib works by blocking this specific protein — so it only helps when your tumour carries that rearrangement.
The test is done on tumour tissue, usually from the biopsy you have already had. The laboratory looks for the ALK rearrangement using one of several approved methods: FISH, immunohistochemistry, or next-generation sequencing. A positive result means alectinib targets the mechanism driving your cancer.
If your original biopsy sample was too small or degraded, a new sample may be needed before the question can be answered. This is not a sign that your cancer has changed — it is a technical requirement of the test.
Which criteria make you eligible for alectinib?
- Your lung cancer is non-small cell type (usually adenocarcinoma)
- A biopsy or tissue sample has been taken from your tumour
- The tissue has been tested for the ALK gene rearrangement
- The ALK test result came back positive
- You have not previously been treated with alectinib
- Your oncologist has confirmed which treatment setting applies to you — first-line, after surgery, or after crizotinib
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
In which situations is alectinib approved?
| Your situation | Alectinib appropriate? | What to know |
|---|---|---|
| ALK-positive metastatic NSCLC, no prior ALK treatment | Yes — recommended | NCCN and ESMO list alectinib as a preferred first-line option for metastatic ALK-positive NSCLC |
| ALK-positive NSCLC, after surgery (stage IB–IIIA) | Yes — adjuvant setting | Approved to reduce the risk of recurrence after the tumour has been surgically removed |
| ALK-positive NSCLC, after crizotinib stopped working | Yes — second-line option | Alectinib has demonstrated activity after crizotinib in a proportion of patients |
| ALK-negative NSCLC | No | Alectinib targets the ALK protein — it cannot work without the rearrangement |
| EGFR-mutated NSCLC (no ALK rearrangement) | No | A different class of targeted therapy — an EGFR inhibitor — is the appropriate treatment |
| Small cell lung cancer | No | Alectinib is not approved or indicated for small cell lung cancer |
| ALK-positive after alectinib has already failed | Discuss with your oncologist | A different ALK inhibitor such as lorlatinib may be considered; the options depend on your individual situation |
What else do you need to know before starting alectinib?
I have never smoked — does that affect my eligibility?
Smoking history does not change the eligibility criteria. What decides eligibility is the ALK test result from your tumour tissue alone. That said, ALK-positive lung cancer is diagnosed more often in people who have never smoked or smoked lightly compared to the broader lung cancer population. If you have never smoked and your oncologist has not mentioned ALK testing, it is reasonable to ask whether it has been done — it can change your treatment entirely. Your answer lies in the test result, not in your history.
The cancer has spread to my brain — can I still take alectinib?
Brain spread does not prevent you from being eligible for alectinib. Alectinib crosses the blood-brain barrier more effectively than the first generation of ALK inhibitors, and NCCN and ESMO guidelines recognise it has meaningful activity against brain metastases. Your oncologist may also recommend additional treatment for the brain — such as stereotactic radiosurgery — depending on the number and size of the lesions. Having brain metastases changes how your overall plan is managed, but it does not on its own mean alectinib is off the table.
What if the ALK test result comes back unclear or borderline?
An unclear or borderline result is not a final answer. Your oncologist may request repeat testing on a different tissue sample, or use a second method to confirm — for example, if immunohistochemistry gave a weak positive, FISH or next-generation sequencing may be used for confirmation. In some cases the original sample is inadequate and a new biopsy is needed. Starting a targeted therapy based on an uncertain result exposes you to real side effects without the expected benefit, which is why confirming the result before starting matters.
Can I take alectinib if I am pregnant or planning to get pregnant?
Alectinib may harm a developing baby and is not recommended during pregnancy. If you are pregnant at diagnosis, your oncologist and an obstetrician will advise together on options and timing. Effective contraception is recommended for both women and men during treatment. If you plan to conceive in future, raise this with your team before starting alectinib — there is guidance on safe windows after stopping treatment. Do not stop alectinib on your own without discussing it with your oncologist first.
I have liver problems — does that affect whether I can take alectinib?
Liver function affects how alectinib is processed by the body, and the drug itself can sometimes raise liver enzymes, which is why regular blood tests are done during treatment. If you have pre-existing liver disease, your oncologist will review your liver function before starting and may adjust the dose or monitor you more closely. Pre-existing liver problems do not automatically rule you out, but your oncologist needs to weigh the likely benefit against the specific risk for your situation before deciding.
Did you know?
ALK rearrangement is found in only a small proportion of all non-small cell lung cancer cases. Among people who have never smoked and whose cancer is of the adenocarcinoma type, it is diagnosed considerably more often than in the broader lung cancer population.
If you have never or rarely smoked and have not been told whether ALK testing was done, ask your oncologist — a positive result changes the treatment plan entirely.
Source: NCCN Clinical Practice Guidelines in Oncology — Non-Small Cell Lung Cancer
Explore 75 more Lung Cancer Targeted Medicines topics
Drug Deep Dive: Alectinib (Alecensa)
- Alectinib (Alecensa, Alectinib): The Complete Patient Guide
- Alectinib After Surgery for Early-Stage ALK-Positive Lung Cancer
- Alectinib Myths: Is ALK-Positive Cancer 'Curable'?
- Alectinib Price in India: Brand, Generic and Monthly Cost
- Alectinib Side Effects: The Complete List and Timeline
- Alectinib Success Rate and Survival: An Honest Look at the Numbers
- Alectinib and Brain Metastases: How It Protects the Brain
- Alectinib in Elderly Patients and Those With Other Illnesses
- Alectinib vs Crizotinib vs Lorlatinib: Choosing an ALK Inhibitor
- Diet and Nutrition While on Alectinib
- Do You Need Chemotherapy Alongside Alectinib?
- Drug, Food and Supplement Interactions With Alectinib
- Fertility, Pregnancy and Contraception on Alectinib
- How Does Alectinib Work? The Second-Generation ALK Inhibitor Explained
- How Long Does Alectinib Take to Work?
- How Long Will You Stay on Alectinib?
- Muscle Pain and High CPK on Alectinib: When to Worry
- Severe Sun Sensitivity on Alectinib: Preventing Serious Burns
- Taking Alectinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Alectinib
- Weight Gain, Constipation and a Slow Pulse on Alectinib
- When Alectinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Alectinib? ALK-Positive Lung Cancer
- Will Insurance or a Government Scheme Pay for Alectinib?
- Work, Travel and Daily Life on Alectinib
Drug Deep Dive: Gefitinib (Iressa)
- Diarrhoea on Gefitinib: Home Management and Warning Signs
- Diet and Nutrition While on Gefitinib
- Fertility, Pregnancy and Contraception on Gefitinib
- Gefitinib (Iressa, Geftinat, Geftib): The Complete Patient Guide
- Gefitinib Myths: 'It's Only for Poor Patients' and Other Half-Truths
- Gefitinib Plus Chemotherapy: Does Adding Chemo Actually Help?
- Gefitinib Price in India: Brand, Generic and Monthly Cost
- Gefitinib Rash: Why It Appears in Week Two and How to Treat It
- Gefitinib Side Effects: The Complete List and Timeline
- Gefitinib Success Rate and Survival: An Honest Look at the Numbers
- Gefitinib and Antacids: The Interaction That Silently Reduces Absorption
- Gefitinib in Early-Stage vs Advanced Lung Cancer: Different Goals
- Gefitinib in Elderly Patients and Those With Other Illnesses
- Gefitinib vs Osimertinib: Making the Decision When Cost Matters
- How Does Gefitinib Work? The First-Generation EGFR Inhibitor Explained
- How Long Does Gefitinib Take to Work?
- How Long Will You Stay on Gefitinib?
- Raised Liver Enzymes on Gefitinib: What Your LFT Report Means
- T790M Testing After Gefitinib Stops Working: The Next Step Explained
- Taking Gefitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Gefitinib
- When Gefitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Gefitinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Gefitinib?
- Work, Travel and Daily Life on Gefitinib
Drug Deep Dive: Osimertinib (Tagrisso)
- Adjuvant Osimertinib After Lung Cancer Surgery: Three Years of Tablets
- Breathlessness or New Cough on Osimertinib: Recognising Lung Injury (ILD)
- Diet and Nutrition While on Osimertinib
- Drug, Food and Supplement Interactions With Osimertinib
- Fertility, Pregnancy and Contraception on Osimertinib
- Heart Rhythm and Ejection Fraction Changes on Osimertinib
- How Does Osimertinib Work? The Third-Generation EGFR Inhibitor Explained
- How Long Does Osimertinib Take to Work?
- How Long Will You Stay on Osimertinib?
- Osimertinib (Tagrisso): The Complete Patient Guide
- Osimertinib Myths: Clear Scans, Stopping Early and Generic Quality
- Osimertinib Price in India: Brand, Generic and Monthly Cost
- Osimertinib Side Effects: The Complete List and Timeline
- Osimertinib Success Rate and Survival: An Honest Look at the Numbers
- Osimertinib With Chemotherapy: Who Actually Benefits From the Combination?
- Osimertinib and Brain Metastases: Why It Works Inside the Brain
- Osimertinib in Elderly Patients and Those With Other Illnesses
- Osimertinib vs Gefitinib and Erlotinib: Is the Costlier Drug Worth It?
- Rash, Dry Skin and Nail Problems on Osimertinib
- Taking Osimertinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Osimertinib
- When Osimertinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Osimertinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Osimertinib?
- Work, Travel and Daily Life on Osimertinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does my cancer type determine whether I can take alectinib?
Yes. Alectinib is approved only for non-small cell lung cancer, most commonly adenocarcinoma. Small cell lung cancer and other cancer types are not treated with alectinib. Even within non-small cell lung cancer, you need a positive ALK result — the diagnosis alone is not enough. Your pathology report from the biopsy will state the cancer type. If the language is unclear, ask your oncologist to walk you through it.
How long does ALK testing take?
Most ALK results come back within one to two weeks from when the laboratory receives the sample. Next-generation sequencing — which tests for multiple biomarkers at once — can take a little longer. If the original biopsy sample is too small, a new sample may be needed and this adds time. Ask your team when the sample was sent and when the result is expected, so you are not left waiting without a timeline.
What happens if alectinib eventually stops working?
If alectinib loses its effect over time, your oncologist will reassess. For ALK-positive lung cancer, other ALK inhibitors — such as lorlatinib or brigatinib — may be options. A repeat biopsy on a new sample can sometimes identify resistance changes that guide the next treatment choice. The evidence on the best sequence of ALK inhibitors is still developing. Asking your oncologist what the plan would be if this treatment stops working is a reasonable question to raise before or during treatment.
Is alectinib available through CION?
Alectinib is a tablet taken at home, not an infusion given in a clinic. CION supports you during treatment with regular blood tests — including liver function monitoring — and coordinates response-assessment scans such as PET-CT with partner imaging centres. CION does not supply or stock medicines; alectinib is dispensed by a pharmacy on prescription from your oncologist. Your CION team can advise on where to obtain it and what to expect regarding cost.
Can alectinib be taken alongside chemotherapy or radiotherapy?
Alectinib is typically given on its own as a targeted therapy, not combined with standard chemotherapy in routine practice. Radiotherapy may be used alongside it in specific circumstances — for example, to manage brain lesions that need additional control. If you are on other treatments or medicines, including supplements and herbal remedies, tell your oncologist before starting alectinib so they can check for interactions.
What is the difference between ALK-positive and EGFR-mutated lung cancer?
Both are types of non-small cell lung cancer driven by a specific genetic change, but the changes are different and require different drugs — alectinib for ALK-positive, an EGFR inhibitor for EGFR-mutated. The tests for each are separate. Having one does not rule out the other, though carrying both is uncommon. If your oncologist tested only for one marker, it is reasonable to ask whether the other has been checked — getting the right match between tumour and treatment is the whole point of biomarker testing.